{"id":17245,"date":"2021-11-03T15:00:29","date_gmt":"2021-11-03T14:00:29","guid":{"rendered":"http:\/\/mabdesign.fr\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/"},"modified":"2021-11-03T15:00:29","modified_gmt":"2021-11-03T14:00:29","slug":"biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/","title":{"rendered":"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million"},"content":{"rendered":"

November 3, 2021 – Biomunex Pharmaceuticals<\/strong>, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M) in grants from the French government as part of the \u2018Grand D\u00e9fi Biom\u00e9dicament\u2019 scheme. A total budget of \u20ac5.6 million ($6.5M) is allocated to this project. To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-17245","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members"],"yoast_head":"\nBiomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million - MabDesign<\/title>\n<meta name=\"description\" content=\"Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-03T14:00:29+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million\",\"datePublished\":\"2021-11-03T14:00:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\"},\"wordCount\":73,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\",\"name\":\"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2021-11-03T14:00:29+00:00\",\"description\":\"Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million - MabDesign","description":"Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/","og_locale":"en_US","og_type":"article","og_title":"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million - MabDesign","og_description":"Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).","og_url":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/","og_site_name":"MabDesign","article_published_time":"2021-11-03T14:00:29+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million","datePublished":"2021-11-03T14:00:29+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/"},"wordCount":73,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/","url":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/","name":"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2021-11-03T14:00:29+00:00","description":"Biomunex Pharmaceuticals, a biopharmaceutical company that develops cutting-edge immunotherapy through the discovery and development of bi- and multi-specific antibodies, today announces that its BiXAb5 project has received close to \u20ac3 million ($3.5M).","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/biomunex-pharmaceuticals-breakthrough-immunotherapy-project-receives-grants-close-to-e3-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Biomunex Pharmaceuticals\u2019 breakthrough immunotherapy project receives grants close to \u20ac3 million"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17245"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17245\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}